FAQs

What does Augme® Technologies do?

What does Augme® Technologies do?

Augme® Technologies, Inc. (OTC.BB: AUGT - News) provides strategic services and mobile marketing technology to leading consumer and healthcare brands. Its platforms, including AD LIFE™, have provided measurable successes across an industry-leading 150,000+ campaigns for such clients as Macy’s, MillerCoors, Nestle, KFC, and Clear Channel. Augme’s® offerings allow marketers, brands, and agencies the ability to plan, create, test, deploy, and track mobile marketing programs across every mobile channel, including SMS, 2D/QR codes, mobile websites, advertising networks, social media and branded apps. Augme’s® platforms facilitate consumer brand interaction and the ability to track and analyze campaign results. Using its own patented device-detection and proprietary mobile content adaptation software, AD LIFE™ solves the mobile marketing industry problem of disparate operating systems, device types, and on-screen mobile content rendering. Augme® also provides business to consumer utilities including national mobile couponing solutions, strategic mobile healthcare tools, custom mobile application development, and consumer data tracking and analytics. In addition to AD LIFE™, Augme® owns Hipcricket and licenses the digital broadcast platform BOOMBOX®. Augme® is headquartered in New York City, with operations in Seattle, Atlanta, Dallas, Los Angeles, Chicago, Tucson, San Francisco, and Miami.

Augme® Technologies, Inc., Augme®, AD LIFE, BOOMBOX®, AD SERVE™ and the Augme® logo are trademarks of Augme® Technologies, Inc. All rights reserved. 2009-11.

What does Hipcricket do?

What does Hipcricket do?

Hipcricket, owned by Augme® Technologies, Inc. Inc. (OTC.BB: AUGT - News), is the one-stop mobile marketing and advertising company that empowers brands, agencies and media properties to engage customers, drive loyalty and increase sales. Hipcricket’s customers connect with consumers across every mobile channel, including SMS, 2D/QR codes, mobile websites, advertising networks, social media and branded apps. Hipcricket’s proven technology, strategic and marketing services and experienced account management teams have provided measurable successes across an industry-leading 150,000 campaigns for such clients as Macy’s, MillerCoors, Nestle, KFC, and Clear Channel. The company has also created the first comprehensive permission-based mobile ad network that taps into the buying power of the mass market with industry-leading capabilities to target customers via location and highly-specific demographic information across SMS, display, rich media and video. Hipcricket is based in Seattle, Washington, with operations in New York, Dallas, Chicago, Atlanta, Los Angeles, San Francisco, and Miami. For more mobile marketing and mobile advertising information, please visit www.hipcricket.com.

What stock exhange does Augme® Technologies trade on and what is its ticket symbol?

What stock exhange does Augme® Technologies trade on and what is its ticket symbol?

Augme® Technologies' shares are traded on the Over the Counter Bulletin Board (OTCBB) under the ticker symbol AUGT.

Where are Augme® Technologies' headquarters located?

Where are Augme® Technologies' headquarters located?

Augme® Technologies’ headquarters are located at 350 7th Avenue, 2nd Floor, New York, NY 10001. Our telephone number is (855) 423-5433.

Who should I contact regarding my Augme® Technologies stock certificate?

Who should I contact regarding my Augme® Technologies stock certificate?

Manhattan Transfer Registrar is Augme® Technologies' transfer agent and administers all matters related to stock that is directly registered with Augme® Technologies.
Contact:
Manhattan Transfer Registrar
57 Eastwood Road
Miller Place, NY 11764
www.mtrco.com (631)-928-7655 Office (631)-928-6171 Fax

If your stock is held by a brokerage firm, please contact your broker directly.

Who is the Transfer Agent for Augme® Technologies?

Who is the Transfer Agent for Augme® Technologies?

Manhattan Transfer Registrar is Augme® Technologies' transfer agent and administers all matters related to stock that is directly registered with Augme® Technologies.
Contact:
Manhattan Transfer Registrar
57 Eastwood Road
Miller Place, NY 11764
www.mtrco.com (631)-928-7655 Office (631)-928-6171 Fax

If your stock is held by a brokerage firm, please contact your broker directly.

When does Augme® Technologies’ fiscal year end?

When does Augme® Technologies’ fiscal year end?

Augme® Technologies’ fiscal year ends February 29, 2012.

How do I request financial materials?

How do I request financial materials?

Please refer to the Financial Reporting tab on our website where you can download the appropriate materials.

Does Augme® Technologies pay dividends?

Does Augme® Technologies pay dividends?

Augme® Technologies does not intend to declare or pay cash dividends on its capital stock in the foreseeable future.

Does Augme® Technologies have a direct purchase plan for its common stock?

Does Augme® Technologies have a direct purchase plan for its common stock?

Augme® Technologies does not currently offer a direct stock purchase plan. Our stock can be purchased or sold through a financial institution such as a brokerage firm. Augme® Technologies is working on establishing such a plan.

Who are Augme® Technologies’ independent accountants?

Who are Augme® Technologies’ independent accountants?

Augme® Technologies’ independent accountants are Moss Adams LLP.

How can I get a copy of Augme® Technologies’ prospectus?

How can I get a copy of Augme® Technologies’ prospectus?

A copy of the final prospectus relating to this offering may be obtained from Augme® Technologies’ Headquarters located in New York at 350 7th Avenue, 2nd Floor, New York, NY 10001. Our telephone number is (855) 423-5433. Alternatively you can visit www.sec.gov.

When was Augme® Technologies incorporated?

When was Augme® Technologies incorporated?

Founded in 1999 the Company provided strategic services and mobile technology to leading consumers and healthcare brands. The Company, formerly known as Modavox, Inc., changed its name to Augme® Technologies, Inc. in February 2010. Augme® is a Delaware Corporation.

Who were the underwriters for Augme® Technologies’ recent secondary offering?

Who were the underwriters for Augme® Technologies’ recent secondary offering?

Augme® Technologies completed a $20.2M Public Offering. Northland Capital Markets acted as the lead bookrunner, and ThinkEquity LLC and Brean Murray, Carret & Co. acted as co-managers in the offering.

How many common shares of stock are authorized by Augme® Technologies?

How many common shares of stock are authorized by Augme® Technologies?

250 million.

How many common shares of Augme® Technologies stock are outstanding?

How many common shares of Augme® Technologies stock are outstanding?

Approximately 84 million.

How many preferred shares of stock are authorized Augme® Technologies?

How many preferred shares of stock are authorized Augme® Technologies?

25 million.

How many preferred shares of Augme® Technologies stock are outstanding?

How many preferred shares of Augme® Technologies stock are outstanding?

None.

Does Augme® Technologies have any long-term or short-term debt?

Does Augme® Technologies have any long-term or short-term debt?

No.

How many Augme® Technologies’ options and warrants are outstanding?

How many Augme® Technologies’ options and warrants are outstanding?

Approximately 28 million.

What is the average exercise price of Augme® Technologies’ options and warrants?

What is the average exercise price of Augme® Technologies’ options and warrants?

Approximately $2.02 per share.

Are there any other questions you may have that haven't been answered?
Please submit your questions using the form below. *Required Fields

Augme Technologies, Inc.™, Augme®, AD LIFE®, BOOMBOX®, AD SERVE™, hipcricket® and the Augme and hipcricket logos are trademarks of Augme Technologies, Inc. All rights reserved. 2009-11. Content and process described all or in part protected by the following U.S. Patents: 6,594,691, 7,269,636, 7,783,721, 7,831,690 , 7,958,081, 8,069,168, 8,069,169 and patents pending.